BioAge Labs, Inc. (NASDAQ:BIOA) Given Consensus Rating of “Moderate Buy” by Brokerages

BioAge Labs, Inc. (NASDAQ:BIOA) has received an average rating of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $43.50.

Several research analysts have weighed in on the company. BTIG Research assumed coverage on BioAge Labs in a report on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price target for the company. Needham & Company LLC assumed coverage on BioAge Labs in a report on Friday, March 27th. They issued a “buy” rating and a $50.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Roth Mkm began coverage on BioAge Labs in a report on Wednesday, May 27th. They issued a “buy” rating and a $36.00 price target for the company. Finally, Citigroup upped their price objective on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th.

BioAge Labs Stock Performance

Shares of BIOA opened at $24.95 on Tuesday. The stock has a fifty day moving average of $18.21 and a two-hundred day moving average of $18.00. The company has a market capitalization of $1.11 billion, a PE ratio of -10.40 and a beta of 0.94. BioAge Labs has a fifty-two week low of $4.07 and a fifty-two week high of $25.80.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.19. The company had revenue of $2.77 million during the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. As a group, equities research analysts forecast that BioAge Labs will post -2.68 earnings per share for the current fiscal year.

Institutional Trading of BioAge Labs

Institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. acquired a new stake in shares of BioAge Labs during the 3rd quarter worth $27,000. CWM LLC increased its holdings in shares of BioAge Labs by 39.9% during the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after buying an additional 1,053 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of BioAge Labs by 85.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after buying an additional 5,976 shares during the last quarter. Walleye Capital LLC acquired a new stake in shares of BioAge Labs during the 2nd quarter worth $64,000. Finally, Bank of America Corp DE increased its holdings in shares of BioAge Labs by 46.3% during the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after buying an additional 3,517 shares during the last quarter.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.